- Trials with a EudraCT protocol (148)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
148 result(s) found for: Left ventricle.
Displaying page 6 of 8.
EudraCT Number: 2011-003025-10 | Sponsor Protocol Number: VIVID | Start Date*: 2011-11-08 | |||||||||||||||||||||
Sponsor Name:King's College London [...] | |||||||||||||||||||||||
Full Title: Effect of active vitamin-D treatment on left ventricular hypertrophy in patients with type-2 diabetes and stage-3 chronic kidney disease. | |||||||||||||||||||||||
Medical condition: Left ventricular hypertrophy, type 2 diabetes, chronic kidney disease. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-004154-25 | Sponsor Protocol Number: CLCZ696B2319E1 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A multicenter study to evaluate long-term safety and tolerability of open label sacubitril/valsartan in pediatric patients with heart failure due to systemic left ventricle systolic dysfunction wh... | |||||||||||||
Medical condition: Pediatric heart failure : Patients (≥ 13 months) with HF due to systemic left ventricular systolic dysfunction. [Note: All patients per protocol for the core study CLCZ696B2319 (PANORAMA-HF) ... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) FR (Completed) BG (Completed) PT (Completed) CZ (Completed) ES (Ongoing) HU (Completed) HR (Completed) DE (Completed) AT (Completed) IT (Completed) FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002312-27 | Sponsor Protocol Number: 13-031 | Start Date*: 2013-08-14 | ||||||||||||||||
Sponsor Name:Zealand Pharma | ||||||||||||||||||
Full Title: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess Clinical Efficacy and Safety of Danegaptide in Patients with ST-Elevation Myocardial Infarction undergoing Primary Per... | ||||||||||||||||||
Medical condition: The treatment of acute myocardial infarction, AMI is aimed at enabling the return of blood flow to the ischemic myocardium, thereby limiting the size of the infarct. However the reperfusion by itse... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-003014-28 | Sponsor Protocol Number: FARM12JCXN | Start Date*: 2017-10-30 | |||||||||||
Sponsor Name:UMBERTO I - POLICLINICO DI ROMA | |||||||||||||
Full Title: MULTICENTER RANDOMIZED STUDY ON THE EFFICACY OF IMMUNOSUPPRESSION IN PATIENTS WITH VIRUS-NEGATIVE INFLAMMATORY CARDIOMYOPATHY | |||||||||||||
Medical condition: virus negative inflammatory cardiomyopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022153-42 | Sponsor Protocol Number: ADVANCE | Start Date*: 2011-01-10 | |||||||||||
Sponsor Name:Cytori Therapeutics, Inc | |||||||||||||
Full Title: A phase II trial of safety and efficacy of ADRCs delivered via the intracoronary route in the treatment of patients with ST-elevation acute myocardial infarction – The ADVANCE Trial | |||||||||||||
Medical condition: patients with ST-elevation myocardial infarction after PCI with stent | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001109-22 | Sponsor Protocol Number: PBGM01-001 | Start Date*: Information not available in EudraCT |
Sponsor Name:Passage Bio, Inc. | ||
Full Title: A Phase 1/2 Open-Label, Multicenter, Dose Ranging and Confirmatory Study to Assess the Safety, Tolerability and Efficacy of a Single Dose of PBGM01 Delivered into the Cisterna Magna of Pediatric Su... | ||
Medical condition: GM1 gangliosidosis (GM1) is an autosomal recessive disorder that results from mutations in the human galactosidase beta 1 gene (GLB1), which encodes beta-galactosidase (β-gal). | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004497-15 | Sponsor Protocol Number: ERGO | Start Date*: 2016-12-12 | |||||||||||
Sponsor Name:UMBERTO I - POLICLINICO DI ROMA | |||||||||||||
Full Title: Study on New Insights in Remodeling of Endocrine Cardiomyopathies: Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A in C... | |||||||||||||
Medical condition: Cushing’s Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000823-15 | Sponsor Protocol Number: NEUPRODEX | Start Date*: 2013-12-23 |
Sponsor Name:Charité – Universitätsmedizin Berlin | ||
Full Title: Neuroprotection with Dexmedetomidine in patients undergoing elective cardiac or abdominal surgery | ||
Medical condition: The drug Dexmedetomidine will be investigated in patients (men and women) undergoing elective cardiac or abdominal surgery. The study medication will be administered perioperatively by intravenous ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-000915-26 | Sponsor Protocol Number: CMMo-OCC-2012 | Start Date*: 2013-09-17 | |||||||||||
Sponsor Name:FUNDACIÓN PROGRESO Y SALUD | |||||||||||||
Full Title: Clinical Trial Phase III single-center, open-label efficacy of intracoronary infusion of bone marrow mononuclear cells in patients with occlusion Autologous chronic coronary revascularization and v... | |||||||||||||
Medical condition: Chronic coronary occlusion | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Temporarily Halted) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003843-39 | Sponsor Protocol Number: LEVOCEST | Start Date*: 2018-03-27 | |||||||||||
Sponsor Name:Hospital Universitario de Canarias- Dr. Francisco Bosa Ojeda | |||||||||||||
Full Title: Clinical trial, Phase III, randomized, prospective, unicentric, double-blind and placebo-controlled, to estimate the efficacy and safety of intravenous Levosimendan, in the first 24 hours after pri... | |||||||||||||
Medical condition: acute coronary syndrome with ST-segment elevation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000540-26 | Sponsor Protocol Number: CVT-CV-002 | Start Date*: 2013-05-12 | |||||||||||
Sponsor Name:CVie Therapeutics Company Limited | |||||||||||||
Full Title: The clinical study of the safety and efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure - A multicenter, randomized, double-blind, placebo controlled, parallel group clinical ... | |||||||||||||
Medical condition: Acute heart failure decompensated | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003564-31 | Sponsor Protocol Number: 190580-001 | Start Date*: 2020-01-16 | |||||||||||
Sponsor Name:Aarhus University Hospital | |||||||||||||
Full Title: Low dose catheter directed thrombolysis for acute intermediary-high risk pulmonary embolism. | |||||||||||||
Medical condition: Acute intermediary-high risk pulmonary embolism | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004398-30 | Sponsor Protocol Number: ABX464-108 | Start Date*: 2021-11-29 | |||||||||||
Sponsor Name:Abivax | |||||||||||||
Full Title: A follow-up Phase II open-label study to evaluate the long-term safety and efficacy profile of ABX464 given at 25 mg once daily in subjects with Moderate to Severe Active Ulcerative Colitis | |||||||||||||
Medical condition: Moderate to Severe Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) HU (Trial now transitioned) SK (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) SI (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020497-41 | Sponsor Protocol Number: ANG.AMI-IC001 | Start Date*: 2013-02-13 | |||||||||||
Sponsor Name:Mesoblast, Inc. | |||||||||||||
Full Title: A prospective, double blind, randomized, placebo-controlled clinical trial of intracoronary infusion of immunoselected, bone marrow-derived Stro3 mesenchymal precursor cells (MPC) in the treatment ... | |||||||||||||
Medical condition: ST-elevation myocardial infarction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) NL (Completed) DK (Completed) SE (Completed) CZ (Completed) AT (Prematurely Ended) PL (Completed) IT (Prematurely Ended) ES (Completed) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005329-26 | Sponsor Protocol Number: CV027-031 | Start Date*: 2023-01-24 | ||||||||||||||||
Sponsor Name:Myokardia, Inc. | ||||||||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy | ||||||||||||||||||
Medical condition: Symptomatic Nonobstructive Hypertrophic Cardiomyopathy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) NO (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) IT (Prematurely Ended) NL (Ongoing) PL (Trial now transitioned) BE (Trial now transitioned) CZ (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000302-12 | Sponsor Protocol Number: BUC-CLIN-303 | Start Date*: 2016-07-13 | |||||||||||
Sponsor Name:ARCA biopharma, Inc. | |||||||||||||
Full Title: GENETIC-AF – A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure | |||||||||||||
Medical condition: Atrial Fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) NL (Completed) PL (Completed) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005514-40 | Sponsor Protocol Number: BO-001 | Start Date*: 2008-10-08 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Universitätslehrkrankenhaus Hall in Tirol | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Endothelin Receptor Blockade in Heart Failure with Diastolic Dysfunction and Pulmonary Hypertension Randomisierte, placebokontrollierte, multizentrische, doppel- blinde Pilotstudie zur Untersuchu... | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Heart failure with normal left ventricle systolic function (HFNEF) are common causes of hospitalisation mainly in the elderly population and are frequently associated with pulmonary hypertension. I... | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: AT (Ongoing) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000552-25 | Sponsor Protocol Number: DS9231-A-U201 | Start Date*: 2017-08-07 | ||||||||||||||||
Sponsor Name:Daiichi Sankyo Inc. | ||||||||||||||||||
Full Title: Evaluation of Safety and Thrombolytic Effect of Ascending Doses of DS-9231 (TS23) in Subjects with Intermediate-Risk (sub-massive) Acute Pulmonary Embolism (PE) | ||||||||||||||||||
Medical condition: DS9231, also known as TS23, is an inhibitor of alpha2-antiplasmin, incrasing plasmin acitivy and enhances fibrinolysis (thrombolysis) and intended to be used for the treatment of patients with Inte... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-003280-26 | Sponsor Protocol Number: IMB101-005 | Start Date*: 2020-11-09 | |||||||||||
Sponsor Name:Imbria Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Dose-Ranging Pharmacodynamic Study to Evaluate the Effects of IMB-1018972 on Myocardial Energetics, Metabolism, and Function in Patients with Type 2 Diabetes | |||||||||||||
Medical condition: Diabetic Cardiomyopathy (DbCM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000773-71 | Sponsor Protocol Number: vem+IL-2v1.0 | Start Date*: 2013-07-12 | |||||||||||
Sponsor Name:Department of Oncology, Aarhus University Hospital | |||||||||||||
Full Title: A multicenter phase II study evaluating the efficacy and tolerability of vemurafenib in combination with Pegylated Interferon and Interleukin-2 in patients with BRAF-mutated metastatic melanoma | |||||||||||||
Medical condition: Metastatic melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
